Ben R. Taft, PhD

Senior Director of Chemistry, Via Nova Therapeutics

Bio

Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space.

__wf_예약_상속
약물 발견
CAS 기사 시리즈 중 하나인 이 신약 개발의 도전과 기회에서는 Via Nova Therapeutics의 화학 부문 선임 디렉터인 Ben Taft와 함께 구조-활성-관계 연구와 생물 활성 데이터의 가능한 범위에 대해 알아봅니다.
|Article